Dollfus S, Petit M, Menard J F, Lesieur P
University of Rouen, Department of Psychiatry.
J Autism Dev Disord. 1992 Mar;22(1):47-60. doi: 10.1007/BF01046402.
An alteration of dopaminergic (DA) function much more complex than simple hyperactivity has been evoked in infantile autism. We therefore compared the clinical efficacy of a DA antagonist (amisulpride) and a DA agonist (bromocriptine) in a randomized, double-blind, crossover trial in 9 children with autism, likely severely mentally retarded. Amisulpride acts preferentially on specific autistic symptoms whereas bromocriptine acts more on motor hyperactivity and attention symptoms. These findings raise the specificity of these two drugs which appear to act preferentially on some target symptoms and are consistent with some clinical and pharmacological observations showing a sedative effect with low doses of DA agonists and a stimulant effect with low doses of DA antagonists such as the benzamides.
婴儿自闭症中引发的多巴胺能（DA）功能改变远比单纯的多动更为复杂。因此，我们在一项随机、双盲、交叉试验中，比较了DA拮抗剂（氨磺必利）和DA激动剂（溴隐亭）对9名可能患有严重智力迟钝的自闭症儿童的临床疗效。氨磺必利优先作用于特定的自闭症症状，而溴隐亭对多动和注意力症状的作用更强。这些发现提高了这两种药物作用的特异性，它们似乎优先作用于某些目标症状，这与一些临床和药理学观察结果一致，即低剂量DA激动剂有镇静作用，低剂量DA拮抗剂如苯甲酰胺类有兴奋作用。
